3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lung Neoplasms
2
Breast Neoplasms
2
Stomatitis
1
Rectal Neoplasms
1
Periodontitis
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Febrile Neutropenia
1
EGFR-Mutant Lung Cancer
1
Deglutition Disorders
1
Communication Disorders
1
Colorectal Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma
1
Interventions
Imatinib Mesylate
67
Sunitinib
27
nilotinib
14
regorafenib
13
ripretinib
10
avapritinib
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
Laparoscopy
4
CTLA-4 Antigen
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
trametinib
2
tanespimycin
2
ponatinib
2
pembrolizumab
2
masitinib
2
famitinib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Stromal Tumors
×
Lead
×
Clear all
NCT02800330
2018-08-02
REGORA
Erasmus Medical Center
Phase 4
Completed
31 enrolled